Retinoic acid and ascorbate synergize to suppress myeloid leukemia via TET2 activation.

Cell Rep · 2025 · PMC12676480 · PMID 41037397

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In primary human CD34 + cells from patients with AML, lower overall basal levels of TET2 expression were observed compared to heathy donor (HD) control CD34 + cells, and those with the lowest levels showed a trend toward stronger upregulation and differentiation potential in response to ATRA treatment, as seen in the most responsive human AML cell lines ( Figures 5G , 5H , and S7H – S7K ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.